middle.news

Imugene Raises A$20 Million to Accelerate Cancer Immunotherapy Trials

7:03pm on Monday 2nd of June, 2025 AEST Healthcare
Read Story

Imugene Raises A$20 Million to Accelerate Cancer Immunotherapy Trials

7:03pm on Monday 2nd of June, 2025 AEST
Key Points
  • A$20 million received from convertible notes issuance to CVI Investments
  • First tranche of a planned A$46 million capital raising
  • Funds earmarked for clinical trials of azer-cel, onCARlytics, and VAXINIA
  • Convertible notes feature zero-coupon, five-year maturity, and conversion premium
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Imugene (ASX:IMU)
OPEN ARTICLE